By mutual agreement, Amgen (NASDAQ:AMGN), collaboration partner Novartis (NYSE:NVS) and Banner Alzheimer’s Institute will terminatedevelopment of BACE1 inhibitor CNP520 (umibecestat) for the potential prevention of Alzheimer’s disease due to lack of efficacy.
Preliminary data from two Phase 2/3 studies showed a worsening of some measure of cognitive function in the treatment groups.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.